BASF Pharma Ingredients and Services - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BASF Pharma Ingredients and Services


Ludiflash® is a combined filler, binder and disintegrant, designed to dissolve in the mouth within seconds.

Ludiflash® comprises the following ingredients: 90 percent Mannitol, a fast-dissolving filler with a mildly sweet taste; 5 percent Kollidon® CL-SF (crospovidone), a superior tablet disintegrant that is effective even with very little liquid; and 5 percent Kollicoat® SR 30 D (polyvinyl acetate), a hydrophobic binder. Each component complies with all leading pharmacopoeia monographs. Plus, the fast-disintegrating, fast-acting formulations created with Ludiflash® offer an exceptionally smooth and creamy mouthfeel – enhancing patient compliance.

Ludiflash® delivers tangible benefits to manufacturers, exhibiting good flowability, compressibility and stability. The compound’s low hygroscopicity ensures the stability of the active ingredient and of the tablet itself.

Ludiflash® is suitable for direct compression and roller compaction, and can be deployed in wet-granulation processes. Blends can be processed on standard tableting machines or used in the form of granulate or powder. When a standard tableting process is used, Ludiflash® ensures excellent uniformity, even at high speeds: creating compact and highly porous tablets that offer exceptional hardness and low friability, making them suitable for polyethylene containers and push-through blisters.

www.pharma-ingredients.basf.com/Ludiflash/Home.aspx

pharma-ingredients@basf.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here